(NASDAQ: NBTX) Nanobiotix Sa's forecast annual revenue growth rate of 81.25% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.28%, and while it is forecast to beat the US market's average forecast revenue growth rate of 25.62%.
Nanobiotix Sa's revenue in 2025 is $11,950,588.On average, 7 Wall Street analysts forecast NBTX's revenue for 2025 to be $1,607,004,694, with the lowest NBTX revenue forecast at $1,087,254,564, and the highest NBTX revenue forecast at $2,740,518,226. On average, 7 Wall Street analysts forecast NBTX's revenue for 2026 to be $3,802,737,958, with the lowest NBTX revenue forecast at $709,079,064, and the highest NBTX revenue forecast at $5,986,653,238.
In 2027, NBTX is forecast to generate $2,833,711,475 in revenue, with the lowest revenue forecast at $567,263,251 and the highest revenue forecast at $5,520,686,996.